Pneumococcal Disease News and Research

RSS

Pneumococcal disease describes a group of illnesses caused by the bacterium Streptococcus pneumoniae, also known as pneumococcus. This bacterial pathogen, which affects both children and adults, is a major cause of death and illness worldwide. In fact, according to the World Health Organization (WHO), pneumococcal disease is the number one vaccine-preventable cause of death in children younger than 5 years of age worldwide.

Pfizer's Prevenar 13 granted European marketing authorization

The European Commission has granted Pfizer Inc. a European marketing authorization for its pneumococcal conjugate vaccine, Prevenar 13 (Pneumococcal Polysaccharide Conjugate Vaccine [13-valent, adsorbed]). Prevenar 13 is indicated for active immunization for the prevention of invasive disease, pneumonia, and acute otitis media caused by 13 Streptococcus pneumoniae serotypes in infants and children from 6 weeks to 5 years of age. Invasive pneumococcal disease includes sepsis, meningitis, bacteremia, bacteremic pneumonia, and empyema.

11 Dec 2009

Study reveals that majority of all vaccine preventable deaths occur in those 65 and older

Ninety percent of all vaccine preventable deaths occur in those 65 and older, including residents in nursing homes, according to highlighted studies in the Pennsylvania Patient Safety Authority's 2009 December Patient Safety Advisory.

4 Dec 2009

FDA Advisory Committee votes in support of Pfizer's Prevnar 13

Pfizer Inc announced today that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee voted 10 to 1 that the data presented support the safety and effectiveness of its 13-valent pneumococcal conjugate candidate vaccine, Prevnar 13™ (Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]), for the prevention of invasive pneumococcal disease in infants and young children.

19 Nov 2009

Global health organizations observe World Pneumonia Day; urge governments to take steps to fight pneumonia

Nearly 100 leading global health organizations from around the world joined forces to recognize the first-annual World Pneumonia Day on November 2 and urge governments to take steps to fight pneumonia, the world’s leading killer of young children.

2 Nov 2009

News outlets examine challenges with expanding global child immunization campaigns

Wednesday's release of the WHO, UNICEF and the World Bank joint report on childhood vaccines highlighted gains in recent global vaccination campaigns and also found that nearly 24 million infants worldwide don't get the recommended first-year vaccination.

23 Oct 2009

More infants are being immunized but funding gap leaves millions of children still at risk

Reversing a downward trend, immunization rates are now at their highest ever and vaccine development worldwide is booming, according to a new assessment released today by the World Health Organization (WHO), UNICEF and the World Bank.

22 Oct 2009

PCV vaccines can save the lives of millions of children

A study published in The Cochrane Review this month concludes that pneumococcal conjugate vaccines (PCV), already known to prevent invasive pneumococcal disease (IPD) and x-ray defined pneumonia, was also effective against child deaths.

20 Oct 2009

Deal between GSK, Brazil to strengthen country's pharmaceutical R&D

GlaxoSmithKline (GSK) Chief Executive Andrew Witty on Friday announced Brazil has agreed to buy roughly $2.2 billion of the company's vaccine for pneumococcal disease, Synflorix, for a period of at least eight years, in exchange for a technology transfer, eventually allowing Brazil to manufacture the vaccine itself, the Wall Street Journal reports.

29 Sep 2009

Prevention and treatment of pneumonia are critical to reducing child mortality

New World Health Organization data to be published in this week's edition of the Lancet will shed new light on two leading causes of pneumonia, the world's leading killer of children under age 5, both globally and within specific countries.

14 Sep 2009

Pneumonia-causing diseases kill 1.2m children under 5 annually, Studies say

"Each year 1.2 million children under age 5 die from Streptococcus pneumoniae and Haemophilus influenzae B or Hib," which cause pneumococcal disease and are preventable with vaccines, according to studies published Thursday in the journal Lancet, Reuters reports.

11 Sep 2009

New World Health Organization data emphasizes on two leading causes of pneumonia

New World Health Organization data to be published in this week's edition of The Lancet will shed new light on two leading causes of pneumonia, the world’s leading killer of children under age 5, both globally and within specific countries.

11 Sep 2009

COPD patients to have better protection against pneumonia with new vaccine

A new vaccine against pneumonia may offer better protection from chronic obstructive pulmonary disease (COPD) patients than the currently accepted vaccine, according to recent research that will be published in the September 15 issue of the American Journal of the Respiratory and Critical Care Journal, a publication of the American Thoracic Society.

8 Sep 2009

Health experts appeal for vaccines to be added to national immunization programs

During a recent three-day Asian Vaccine Conference, health experts appealed to countries to add "under-utilised vaccines such as those of pneumococcal, haemophilus influenzae type-b (Hib), and rotavirus" into national immunization programs, the Nation reports.

29 Aug 2009

The Gambia introduces pneumococcal immunisation programme

The Gambia, Minister of Health Dr. Mariatou Jallow administered the first dose of the pneumococcal vaccine to Gambian children at a rural clinic outside Banjul today. Joined by the Gambia’s Vice President, Mrs. Isatou Njie-Saidy, Dr. Jallow and hundreds of Gambian citizens celebrated this historic event, which marks the first step in the rollout of the Gambia’s national pneumococcal immunisation programme.

19 Aug 2009

Asian pneumonia prevention organization calls for required pneumonia vaccine in India

The Asian Strategic Alliance for Pneumococcal Disease Prevention (ASAP) is calling for the pneumonia vaccine to become an official part of India's required list of immunizations, the Times of India reports.

28 Jul 2009

Pneumococcal vaccine effective in preventing severe pneumonia

A new trial has found that pneumococcal vaccine is effective in preventing severe pneumonia, the leading cause of death among children in developing countries. Co-ordinated by the National Institute for Health and Welfare (THL) between 2000 and 2004, a large scale efficacy trial - first of its kind in Asia - was carried out in the Philippines to investigate the effect of an investigational pneumococcal vaccine.

16 Jun 2009

Wall Street Journal examines program to spur vaccine development for developing world diseases

The Wall Street Journal examines a $1.5 billion program supported by Italy, the U.K., Canada, Russia, Norway and the Bill & Melinda Gates Foundation that hopes "to encourage pharmaceutical companies to develop vaccines for diseases common to poor countries," which is expected to be announced Friday "on the sidelines of a meeting of top finance officials from the Group of Eight major industrial powers."

13 Jun 2009

GlaxoSmithKline opens pneumonia vaccine plant In Singapore

Drug maker GlaxoSmithKline (GSK) on Tuesday opened a $600 million plant in Singapore that is slated to begin producing vaccines to fight pneumonia-causing bacteria in 2011, Reuters reports.

10 Jun 2009

Intercell starts trial for Streptococcus pneumoniae vaccine candidate

Intercell AG has announced that a Phase I clinical trial with the company's vaccine candidate IC47 to prevent disease caused by the bacterium Streptococcus pneumoniae has started.

8 Apr 2009

Wyeth's Prevenar vaccine for pneumococcal disease registered in Russia

Wyeth announced today that its 7-valent pneumococcal conjugate vaccine, Prevenar (Pneumococcal saccharide conjugated vaccine, Adsorbed), has been registered by the Russian Ministry of Health and Social Development (Roszdravnadzor) and is expected to be commercially available later this year.

2 Mar 2009